YOLFTbeta
Zentalis Pharmaceuticals Llc

Zentalis Pharmaceuticals Llc

ZNTL · NASDAQ · Healthcare / Biotechnology

1.70USD+0.02 (+1.19%)

Price History

Full chart

Market Stats

Previous Close1.68
Open1.68
Day Range1.63 – 1.76
52-Week Range1.21 – 6.95
Volume1.30M
Market Cap257.03M
P/E (TTM)0.00
Forward P/E0.00
EPS-2.05
Dividend Yield0.00%
Beta1.86
50-Day Avg3.87
200-Day Avg3.40

About

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. It develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types. The company also develops ZN-c3-001, a phase 1 study that evaluated azenosertib monotherapy in solid tumors; and MAMMOTH (ZN-c3-006) is a Phase 1/2 clinical trial of azenosertib in patients with PARP-inhibitor resistant ovarian cancer. It has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC. Zentalis Pharmaceuticals, Inc. was incorporated in 2014 and is based in San Diego, California.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMs. Julie M. Eastland M.B.A.
  • Employees106
  • Headquarters10275 Science Center Dr., San Diego, CA, United States, 92121, USA
  • Websitehttps://zentalis.com

Leadership

  • Ms. Julie M. Eastland M.B.A.CEO, President & Director · b. 1964
  • Mr. James B. Bucher J.D.Chief Legal Officer & Corporate Secretary · b. 1966
  • Dr. Ingmar Bruns M.D., Ph.D.Chief Medical Officer · b. 1975
  • Mr. Vincent A. VultaggioSVP of Finance & Principal Accounting Officer · b. 1984
  • Mr. Robert J. DiVasto P.E.Chief Technical Officer · b. 1956
  • Ms. Wendy ChangChief People Officer
  • Mr. Haibo WangChief Business Officer
  • Mr. Rajesh IsraniExecutive VP of Regulatory Affairs & Medical Writing
  • Mr. Henry GuSenior VP & Head of Intellectual Property
  • Ms. Sarah KellySenior Vice President of Commercial Strategy

Financials

Income Statement

Currency: USD2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue14.00K0000067.42M0
Growth (%)--100.00%------100.00%
Cost of Revenue-111.00K160.00K544.00K1.43M1.39M1.29M739.00K
Gross Profit14.00K-111.00K-160.00K-544.00K-1.43M-1.39M67.42M-739.00K
Gross Margin100.00%-----100.00%-
Operating Expense23.80M46.73M118.63M216.00M225.86M298.12M258.62M152.07M
Operating Income-23.78M-46.84M-118.79M-216.54M-227.29M-299.51M-191.19M-152.81M
Operating Margin-169878.57%------283.57%-
EBITDA-23.73M-46.73M-118.63M-207.20M-233.58M-247.60M-186.17M-144.27M
EBITDA Margin-169514.29%------276.11%-
Net Income-21.07M-45.66M-117.84M-158.72M-236.81M-292.19M-165.84M-137.06M
Net Income Margin-150478.57%------245.96%-
R&D18.92M38.39M84.90M175.60M172.73M235.16M167.77M107.30M
R&D as % of Total Revenue135150.00%-----248.82%-
Interest Expense01.20M2.23M110.05M2.58M---
Interest Expense % of Total Revenue0.00%-------

Balance Sheet

Currency: USD2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets41.00M88.23M365.56M472.02M553.46M562.03M430.34M288.97M
Total Liabilities8.69M19.81M32.18M107.54M119.43M124.64M93.15M72.76M
Total Equity24.77M61.60M308.58M363.95M433.80M437.28M337.19M216.20M
Cash25.15M67.25M54.95M59.96M43.07M28.04M33.90M35.99M
Total Debt-2.48M2.00M45.91M47.33M45.77M42.65M39.58M
Net Debt-25.15M-64.77M-52.95M-14.04M4.26M17.73M8.75M3.58M

Cash Flow

Currency: USD2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-24.25M-39.14M-86.83M-154.09M-163.75M-207.82M-170.86M-125.25M
Investing Cash Flow-227.00K-352.00K-284.83M-18.11M-114.18M-44.46M176.56M131.62M
Financing Cash Flow9.47M81.83M360.44M178.52M261.04M237.30M108.00K-4.28M
Capital Expenditure227.00K352.00K758.00K6.11M2.55M583.00K221.00K0
Free Cash Flow-24.48M-39.49M-87.58M-160.20M-166.30M-208.41M-171.08M-125.25M
FCF to OCF100.94%100.90%100.87%103.96%101.56%100.28%100.13%100.00%

Earnings

Report DateMay 15, 2020Aug 13, 2020Nov 9, 2020Mar 25, 2021May 17, 2021Aug 12, 2021Nov 10, 2021Feb 24, 2022May 5, 2022Aug 9, 2022Nov 9, 2022Mar 1, 2023May 10, 2023Aug 9, 2023Nov 6, 2023Feb 27, 2024May 7, 2024Aug 9, 2024Nov 12, 2024Feb 25, 2025May 14, 2025Aug 6, 2025Nov 10, 2025Mar 26, 2026May 13, 2026Aug 6, 2026Nov 9, 2026
EPS Estimate-0.47-0.49-0.76-0.95-0.91-1.16-1.25-1.49-1.20-1.20-1.19-1.06-1.03-1.02-0.94-0.92-0.74-0.83-0.87-0.68-0.61-0.52-0.48-0.61-0.47-0.45-0.58
EPS Actual-2.88-0.78-0.91-1.01-1.24-1.34-0.09-1.11-1.31-1.34-0.96-0.92-1.07-1.85-0.79-0.930.14-1.24-0.56-0.61-0.67-0.37-0.37-0.49-0.50-0.59-
Surprise-512.77%-59.18%-19.74%-6.32%-36.26%-15.52%92.80%25.50%-9.17%-11.67%19.33%13.21%-3.88%-81.37%15.96%-1.09%118.92%-49.40%35.63%9.96%-9.84%28.85%22.92%19.67%-7.43%-31.11%-
TimingPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hours-After-hours-

Key Statistics & Ratios

Market Cap257.03M
Enterprise Value130.66M
Trailing P/E0.00
Forward P/E0.00
Price / Sales7.13
Price / Book1.89
EPS-2.05
Book Value2.00
Revenue (TTM)26.86M
Gross Profit (TTM)26.86M
EBITDA-149.77M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-66.75%
Return on Assets-33.15%
Shares Outstanding94.67M
Shares Float56.65M
Beta1.86
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Buy
Based on 10 analystsTarget 6.89
  • Strong Buy
    3
  • Buy
    1
  • Hold
    6

Ownership Breakdown

Institutions
50.88%
Insiders
21.88%
Retail / Other
27.24%

Top Institutional Holders

  • 5AM Venture Management, LLC
    3.95M4.02%
  • Squadron Capital Management LLC
    3.70M3.77%
  • Two Sigma Investments LLC
    3.02M3.08%
  • Acadian Asset Management LLC
    2.85M2.90%
  • Vanguard Capital Management, LLC
    2.31M2.35%
  • Citadel Advisors Llc
    2.30M2.34%
  • Renaissance Technologies Corp
    1.94M1.98%
  • Opaleye Management Inc
    1.41M1.44%
  • Decheng Capital LLC
    1.32M1.35%
  • BlackRock Inc
    1.27M1.29%
  • Ishara Investments LP
    1.23M1.25%
  • Bank of America Corp
    1.13M1.15%
  • PRIMECAP Management Company
    957.42K0.98%
  • Pfizer Inc
    953.83K0.97%
  • Soleus Capital Management, L.P.
    950.00K0.97%
  • Connor Clark & Lunn Inv Mgmt Ltd
    792.00K0.81%
  • Millennium Management LLC
    664.28K0.68%

Top Fund Holders

  • Vanguard MStar Total Stk Mkt Idx Invest
    2.86M2.91%
  • iShares Russell 2000 ETF
    1.22M1.24%
  • PRIMECAP Odyssey Aggressive Growth
    676.40K0.69%